Cardio-oncology: The Role of Big Data

Heart Fail Clin. 2017 Apr;13(2):403-408. doi: 10.1016/j.hfc.2016.12.010.

Abstract

Despite its challenges, a "big data" approach offers a unique opportunity within the field of cardio-oncology. A pharmacovigilant approach using large data sets can help characterize cardiovascular toxicities of the rapidly expanding armamentarium of targeted therapies. Creating a broad coalition of data sharing can provide insights into the incidence of cardiotoxicity and stimulate research into the underlying mechanisms. Population health necessitates the use of big data and can help inform public health interventions to prevent both cancer and cardiovascular disease. As a relatively new discipline, cardio-oncology is poised to take advantage of big data.

Keywords: Big data; Cardio-oncology; Pharmacovigilant.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Databases, Factual
  • Heart Diseases / etiology*
  • Humans
  • Information Dissemination
  • Neoplasms / complications
  • Neoplasms / therapy*
  • Pharmacovigilance
  • Survivors

Substances

  • Antineoplastic Agents